← Back to Screener
Enovis Corporation (ENOV)
Price$23.78
Value ScoreB
Growth ScoreD
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-29.37%
Price vs S&P 500 (4W)-10.32%
VGM Score49.88
Market Capitalization$1.37B
All Metrics
P/CF (Annual)6.30x
Book Value / Share (Quarterly)$25.66
P/TBV (Annual)6.02x
Revenue Growth (3Y)12.88%
Cash Flow / Share (Quarterly)$0.62
Price vs S&P 500 (YTD)-18.89%
Gross Margin (TTM)60.41%
Net Profit Margin (TTM)-49.91%
EPS (TTM)$-19.89
10-Day Avg Trading Volume1.06M
EPS Excl Extra (TTM)$-19.89
Revenue Growth (5Y)-6.05%
EPS (Annual)$-20.75
ROI (Annual)-42.51%
Gross Margin (Annual)58.16%
Net Profit Margin (5Y Avg)-17.93%
Cash / Share (Quarterly)$0.58
Revenue Growth QoQ (YoY)5.43%
ROA (Last FY)-30.89%
Revenue Growth TTM (YoY)5.96%
EBITD / Share (TTM)$-15.72
ROE (5Y Avg)-22.31%
Operating Margin (TTM)-47.08%
Cash Flow / Share (Annual)$0.35
P/B Ratio0.93x
P/B Ratio (Quarterly)0.88x
Net Income / Employee (Annual)$-151,800
EV / Revenue (TTM)1.17x
Net Interest Coverage (TTM)-32.29x
ROA (TTM)-26.57%
EV / EBITDA (TTM)74.23x
EPS Incl Extra (Annual)$-20.75
Current Ratio (Annual)2.02x
Quick Ratio (Quarterly)0.97x
3-Month Avg Trading Volume1.05M
52-Week Price Return-24.75%
EV / Free Cash Flow (Annual)133.64x
Revenue / Employee (TTM)$292,000
Tangible BV / Share (Quarterly)$4.94
P/S Ratio (Annual)0.61x
Asset Turnover (Annual)0.59x
52-Week High$36.82
Operating Margin (5Y Avg)-20.71%
EPS Excl Extra (Annual)$-20.75
CapEx CAGR (5Y)11.45%
26-Week Price Return-21.44%
Quick Ratio (Annual)0.97x
13-Week Price Return-2.22%
Total Debt / Equity (Annual)0.87x
Current Ratio (Quarterly)2.04x
Enterprise Value$2.66B
Revenue / Share Growth (5Y)-9.89%
Asset Turnover (TTM)0.53x
Book Value / Share Growth (5Y)-5.69%
Revenue / Employee (Annual)$288,100
Inventory Turnover (Annual)1.66x
Pretax Margin (Annual)-51.57%
Cash / Share (Annual)$0.64
3-Month Return Std Dev60.02%
Gross Margin (5Y Avg)56.70%
Net Income / Employee (TTM)$-145,800
EBITDA Interim CAGR (5Y)-17.15%
ROE (Last FY)-79.51%
Net Interest Coverage (Annual)-30.65x
EPS Basic Excl Extra (Annual)$-20.75
P/FCF (TTM)21.13x
Receivables Turnover (TTM)5.18x
EV / Free Cash Flow (TTM)74.10x
Total Debt / Equity (Quarterly)0.90x
EPS Incl Extra (TTM)$-19.89
Receivables Turnover (Annual)5.29x
ROI (TTM)-35.15%
P/S Ratio (TTM)0.60x
Pretax Margin (5Y Avg)-20.64%
Revenue / Share (Annual)$39.39
Tangible BV / Share (Annual)$4.42
Forward P/E6.52x
Free OCF CAGR (5Y)-36.11%
Price vs S&P 500 (52W)-49.11%
Year-to-Date Return-10.74%
5-Day Price Return9.59%
EPS Normalized (Annual)$-20.75
ROA (5Y Avg)-9.72%
Net Profit Margin (Annual)-52.69%
Month-to-Date Return4.85%
Cash Flow / Share (TTM)$1.86
EBITD / Share (Annual)$-13.46
Operating Margin (Annual)-50.09%
LT Debt / Equity (Annual)0.85x
P/CF (TTM)5.64x
ROI (5Y Avg)-12.77%
LT Debt / Equity (Quarterly)0.87x
EPS Basic Excl Extra (TTM)$-19.89
P/TBV (Quarterly)4.56x
P/B Ratio (Annual)1.02x
Inventory Turnover (TTM)1.52x
Pretax Margin (TTM)-48.34%
Book Value / Share (Annual)$26.05
Price vs S&P 500 (13W)-10.48%
Beta1.46x
P/FCF (Annual)68.73x
Revenue / Share (TTM)$39.75
ROE (TTM)-60.13%
52-Week Low$20.82
vGradeB
gGradeD
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 260.89est. 0.83
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.22
4.22
4.22
4.22
Industry Peers — Orthopedic & Prosthetic Devices(33)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ENOVEnovis Corporation | B | D | C | $23.78 |
| ISRGIntuitive Surgical Inc. | F | B | C | $422.06 |
| EWEdwards Lifesciences Corp | D | C | C | $85.96 |
| STESTERIS plc | C | B | C | $212.35 |
| ZBHZimmer Biomet Holdings, Inc. | B | C | C | $87.33 |
| ALGNAlign Technology Inc | B | C | C | $167.74 |
| SNNSmith & Nephew plc | B | C | C | $30.61 |
| MSAMine Safety Incorporated | B | C | C | $161.30 |
| ESTAEstablishment Labs Holdings Inc. | F | A | B | $74.31 |
| CDRECadre Holdings, Inc. | C | C | D | $30.01 |
| AVNSAvanos Medical, Inc. | B | D | A | $25.05 |
About
Enovis manufactures orthopedic and rehabilitation devices for reconstructive surgery, injury prevention, and pain management. The company serves orthopedic specialists, primary care physicians, physical therapists, and athletic trainers, addressing musculoskeletal conditions ranging from sports injuries and deformities to degenerative diseases. Its Prevention & Recovery segment, which represents the majority of revenue, provides post-surgical rehabilitation and chronic condition management solutions.